Cadrenal Therapeutics, Inc. Common Stock (CVKD) vs iSpecimen Inc. (ISPC)
A side-by-side comparison of Cadrenal Therapeutics, Inc. Common Stock and iSpecimen Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$0.94HealthcareDelayed quote: Oct 6, 2026, 12:37 PM EDT
ISPC
iSpecimen Inc.
$1.06HealthcareDelayed quote: Oct 6, 2026, 12:38 PM EDT
Total return — CVKD vs ISPC
growth of $100 · dividends reinvested · last 4yCVKD -98.5% (-64.8%/yr)ISPC -99.9% (-83.1%/yr)CVKD compounded faster over this window
Log scale — wide-divergence pair
CVKD ISPC
CVKD vs ISPC: by the numbers
- •CVKD is the larger company ($3M vs $3M market cap).
- •Both run net losses; CVKD's is the smaller (0.00% vs -2449.04% net margin).
Metrics side by side
Valuation
| Metric | CVKD | ISPC |
|---|---|---|
| P/S ratio | N/A | 5.70 |
| P/B ratio | 0.82 | 1.53 |
Profitability
| Metric | CVKD | ISPC |
|---|---|---|
| Gross margin | 0.00% | 1.25% |
| Operating margin | 0.00% | -465.42% |
| Net margin | 0.00% | -2449.04% |
| ROE | -282.13% | -657.69% |
| ROIC | -284.81% | -476.39% |
Growth (annualized)
| Metric | CVKD | ISPC |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -46.70% |
| Total return CAGR (5Y) | N/A | -81.14% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.